Scrip
UMN's cell cultured H5N1 vaccine moves forward
22 October 2009
Ian Haydock
Please Login to read the full article.
22 October 2009
Ian Haydock
ian.haydock@informa.com
The Japanese bioventure UMN Pharma has begun a Phase II development programme for UMN-0501, its novel recombinant human vaccine for the H5N1 form of influenza.
Results from the two-centre Japanese trial, to be carried out in 90 healthy adults aged 20-40 years, are expected next February....
Please Login to read the full article.
RELATED CONTENT
NEWS
- Novartis completes first trial of its H1N1 vaccine, says only single dose needed
- UMN in Japanese joint venture for cell-cultured flu vaccines
- US panel gives mixed vote to Protein Sciences' cell-based flu vaccine FluBlok
- Astellas and UMN strike preliminary deal for cell cultured flu vaccines
COMMENT
Other Informa Comment
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
